Patient and transplantation data
| Patient no. . | Age, y* . | Cytogenetics at diagnosis . | EBMT† . | D100 donor chimerism, % . | Total DLI dose,no. of infusions‡ . | Indication . | IM§ . | GVHD‖ . | Complications after transplantation . | Readmission right after transplantation, no. . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | 46,XX,t(9;22)(q34,q11) | 1 | 100 | 0.65 (3) | BCR-ABL | No | 0 | ||
| 2 | 46 | 46,XY,t(9;22),(q34;q11)delder9 | 2 | 100 | 0.65 (3) | BCR-ABL | No | 0 | ||
| 3 | 49 | 46,XX,t(9;22)(q34;q11) | 2 | 100 | 6.65 (5) | BCR-ABL | No | CMV | 0 | |
| 4 | 56 | 46,XY,t(9;22),(q34;q11) | 4 | 100 | None | No | ext | CMV, pneumonia,# died | 91 | |
| 7 | 49 | 46,XY,t(9;22),(q34;q11)delder9 | 2 | 100 | 0.15 (2) | Chimerism | No | EBV,** PCP | 43 | |
| 9 | 39 | 46,XY,t(9;22),(q34;q11) | 2 | 78 | None | Yes | ext | 0 | ||
| 10 | 39 | 46,XY,t(3;9;22)(q21;q34;q11) | 1 | 100 | 4.65 (5) | BCR-ABL | No | 0 | ||
| 11 | 35 | 46,XX,t(9;22)(q34;q11)delder9 | 1 | 90 | 1.65 (4) | Both | Yes | lim | 0 | |
| 12 | 39 | 46,XY,t(9;22),(q34;q11) | 1 | 84 | 1 (1) | Chimerism | No | ext | 0 | |
| 13 | 47 | 46,XX,t(9;22)(q34;q11)delder9 | 2 | 100 | 0.15 (2) | BCR-ABL | Yes | CMV | 0 | |
| 14 | 35 | 46,XX,t(9;22)(q34;q11) | 1 | 80 | 0.15 (2) | Chimerism | No | lim | CMV | 8 |
| 15 | 33 | 46,XX,t(9;22)(q34;q11) | 2 | 100 | 0.6(1) | BCR-ABL | No | lim | EBV,** thyrotoxicosis†† | 2 |
| 16 | 21 | 46,XY,t(9;22),(q34;q11) | 2 | 100 | 1.6 (3) | Both | Yes | lim | 4 | |
| 17 | 47 | 46XX,t(3;15),t(17;22)(p1?3;q11)delder9 | 3 | 100 | 0.1 (1) | Chimerism | No | lim | CMV | 1 |
| 19 | 54 | 46,XX,t(9;22)(q34;q11)delder9 | 2 | 86 | 0.1 (1) | Chimerism | No | CMV | 2 |
| Patient no. . | Age, y* . | Cytogenetics at diagnosis . | EBMT† . | D100 donor chimerism, % . | Total DLI dose,no. of infusions‡ . | Indication . | IM§ . | GVHD‖ . | Complications after transplantation . | Readmission right after transplantation, no. . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | 46,XX,t(9;22)(q34,q11) | 1 | 100 | 0.65 (3) | BCR-ABL | No | 0 | ||
| 2 | 46 | 46,XY,t(9;22),(q34;q11)delder9 | 2 | 100 | 0.65 (3) | BCR-ABL | No | 0 | ||
| 3 | 49 | 46,XX,t(9;22)(q34;q11) | 2 | 100 | 6.65 (5) | BCR-ABL | No | CMV | 0 | |
| 4 | 56 | 46,XY,t(9;22),(q34;q11) | 4 | 100 | None | No | ext | CMV, pneumonia,# died | 91 | |
| 7 | 49 | 46,XY,t(9;22),(q34;q11)delder9 | 2 | 100 | 0.15 (2) | Chimerism | No | EBV,** PCP | 43 | |
| 9 | 39 | 46,XY,t(9;22),(q34;q11) | 2 | 78 | None | Yes | ext | 0 | ||
| 10 | 39 | 46,XY,t(3;9;22)(q21;q34;q11) | 1 | 100 | 4.65 (5) | BCR-ABL | No | 0 | ||
| 11 | 35 | 46,XX,t(9;22)(q34;q11)delder9 | 1 | 90 | 1.65 (4) | Both | Yes | lim | 0 | |
| 12 | 39 | 46,XY,t(9;22),(q34;q11) | 1 | 84 | 1 (1) | Chimerism | No | ext | 0 | |
| 13 | 47 | 46,XX,t(9;22)(q34;q11)delder9 | 2 | 100 | 0.15 (2) | BCR-ABL | Yes | CMV | 0 | |
| 14 | 35 | 46,XX,t(9;22)(q34;q11) | 1 | 80 | 0.15 (2) | Chimerism | No | lim | CMV | 8 |
| 15 | 33 | 46,XX,t(9;22)(q34;q11) | 2 | 100 | 0.6(1) | BCR-ABL | No | lim | EBV,** thyrotoxicosis†† | 2 |
| 16 | 21 | 46,XY,t(9;22),(q34;q11) | 2 | 100 | 1.6 (3) | Both | Yes | lim | 4 | |
| 17 | 47 | 46XX,t(3;15),t(17;22)(p1?3;q11)delder9 | 3 | 100 | 0.1 (1) | Chimerism | No | lim | CMV | 1 |
| 19 | 54 | 46,XX,t(9;22)(q34;q11)delder9 | 2 | 86 | 0.1 (1) | Chimerism | No | CMV | 2 |
Both indicates rising BCR-ABL and mixed chimerism; delder9, deletion of derivative chromosome 9; EBMT, European Group for Blood and Marrow Transplantation; ext, extensive; lim, limited; PCP, Pneumocystis jiroveci pneumonia; and CMV, cytomegalovirus.
The age is at the time of transplantation.
EBMT score is validated for SCT in CML11 (0-7 based on donor type, disease stage, recipient age, donor-recipient sex match, and time from diagnosis to transplant).
DLI dose is × 107CD3+ cells/kg.
Patients receiving IM after transplant.
Chronic GVHD.
¶Patient with grade II acute GVHD (no other patient had acute GVHD).
Pseudomonas species.
EBV+ posttransplant lymphoproliferative disease treated successfully with a single pulse of rituximab.
Autoimmune thyroiditis.